BridgeBio Pharma
Manufacturing · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
3160 Porter Dr Ste 250, Palo Alto, Calif...Phone Number
(650) 391-9740Website
www.bridgebio.comRevenue
$580 MillionStock Symbol
BBIOIndustry
ZI Rank: 5
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
6
7
2
2
3
5
About BridgeBio Pharma
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.Explore more
BridgeBio Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BridgeBio Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once BridgeBio Pharma has new funding data
Congratulate Masked Content for being promoted to Masked Content at BridgeBio Pharma
Competitive Alert! Recent activity has been detected by your competitor Masked Content
BridgeBio Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Check if BridgeBio Pharma has recently received funding, and reach out quickly before it becomes old news!
Check out if BridgeBio Pharma is spiking on competitors!
Click to see if BridgeBio Pharma had a recent Job posting/layoffs
Product Launch: Get notified when BridgeBio Pharma launches new products
Earning: See what the market has to say on BridgeBio Pharma recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined BridgeBio Pharma as Masked Content
Find more new buyers
Compare Similar Companies to BridgeBio Pharma
Compare insights from companies similar to BridgeBio Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BridgeBio Pharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BridgeBio Pharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BridgeBio Pharma.
BridgeBio Pharma financials insights
Gather financial insights about BridgeBio Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series C
$135M
2019
Other Financing Round
$299.2M
2020
Debt
$475M
2021
Debt
$750M
2025
Other Financing Round
$300M
2026
Stock/Share Issuance
$1B
BridgeBio Pharma Tech Stack
A closer look at the technologies used by BridgeBio Pharma
Most Recent Scoops
Open Position
Open Position
Event
Product Marketing, Events, Engineering, Contingent Workforce, Sales, Outsourcing, Bioengineering, Chemical Engineering, Field /Outside Sales, Field Marketing
Open Position
Event
Product Marketing, Events, Business Intelligence, Analytics & Insights, Sales, Pharmaceuticals, Field /Outside Sales, Field Marketing, Operations, Sales Enablement, Sales Operations
BridgeBio Pharma News & Media
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
- The transaction supports the evolution of the Company’s shareholder base toward further high-quality, long-term ownershipBridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today the launch of a secondary public offering of 5,000,000 shares of its common stock by the selling stockholder KKR Genetic Disorder L.P. The Company is not selling any shares and will not receive any of the proceeds of the offering.BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on August 8, 2026, the compensation committee of BridgeBio’s board of directors approved equity grants to 56 new employees in restricted stock units for an aggregate of 66,705 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restriBridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call Transcript
BridgeBio Pharma, Inc. (BBIO) Q2 2026 Earnings Call August 10, 2026 4:30 PM EDTCompany ParticipantsChinmay Shukla - Senior Vice President of Strategic...
Read more news
Top Manufacturing Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BridgeBio Pharma
Sign Up For FreeTo access detailed company insights
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial... Read More
